About Castle Biosciences
Castle Biosciences is a company based in Pittsburgh (United States) founded in 2008 was acquired by Castle Biosciences in October 2021. It operates as a HealthTech. Castle Biosciences has raised $14.18 million across 10 funding rounds from investors including UPMC, Castle Biosciences and NIH. Castle Biosciences offers products and services including TissueCypher, DecisionDx-Melanoma, DecisionDx-SCC, DecisionDx-UM, and MyPath Melanoma. Castle Biosciences operates in a competitive market with competitors including PAVmed, Previse, Cyted, Lucid Diagnostics and BeamLine Diagnostics, among others.
- Headquarter Pittsburgh, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Castle Biosciences, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$14.18 M (USD)
in 10 rounds
-
Latest Funding Round
$2.5 M (USD), Series B
Mar 21, 2018
-
Investors
UPMC
& 7 more
-
Employee Count
Not available
-
Acquired by
Castle Biosciences
(Oct 22, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Castle Biosciences
Castle Biosciences offers a comprehensive portfolio of products and services, including TissueCypher, DecisionDx-Melanoma, DecisionDx-SCC, DecisionDx-UM, and MyPath Melanoma.
Risk of progression to esophageal cancer is predicted.
Melanoma progression risk is assessed for patients.
Squamous cell carcinoma risk is evaluated accurately.
Uveal melanoma metastatic risk is determined precisely.
Melanoma diagnosis is supported through tissue analysis.
Funding Insights of Castle Biosciences
Castle Biosciences has successfully raised a total of $14.18M across 10 strategic funding rounds. The most recent funding activity was a Series B round of $2.5 million completed in March 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Castle Biosciences
Castle Biosciences has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include UPMC, Castle Biosciences and NIH.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health tech startups are invested in by Illumina Ventures.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Investment and support are provided for Pennsylvania's tech-based companies.
|
Locked | Locked | Locked |
Investor details for Castle Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Castle Biosciences
Investment portfolio details for Castle Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Castle Biosciences
Detailed financials for Castle Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Castle Biosciences Comparisons
Peer comparison for Castle Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Castle Biosciences
Castle Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PAVmed, Previse, Cyted, Lucid Diagnostics and BeamLine Diagnostics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of medical devices and biomarkers to detect various diseases
|
|
| Locked | Locked | Locked |
Cancer detection and prevention solutions are developed by Previse.
|
|
| Locked | Locked | Locked |
Non-endoscopic diagnostics for early gastrointestinal disease detection are developed.
|
|
| Locked | Locked | Locked |
Diagnostic kits for esophageal cancer biomarkers are developed.
|
|
| Locked | Locked | Locked |
Offers bedside pre-screening technology solutions for cancer detection.
|
|
| Locked | Locked | Locked |
FDA-cleared swallowable device is used for non-endoscopic GI screening.
|
Detailed competitors of Castle Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Castle Biosciences
Complete news archive for Castle Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Castle Biosciences
Castle Biosciences was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Castle Biosciences is headquartered in Pittsburgh, United States. It is registered at Pittsburgh, Pennsylvania, United States.
Castle Biosciences is a funded company, having raised a total of $14.18M across 10 funding rounds to date.
Precision diagnostic and prognostic tests are developed by Castle Biosciences for various medical conditions. Focus is placed on dermatology, gastroenterology, and ophthalmology sectors. Solutions such as TissueCypher for Barretts esophagus, DecisionDx-Melanoma for cutaneous melanoma, and DecisionDx-UM for uveal melanoma are provided. Risk stratification and personalized patient management are enabled through AI-driven spatial biology and gene expression profiling technologies. Clinical decision-making is supported by offering actionable insights to healthcare providers for cancer risk assessment and treatment planning.
Castle Biosciences's top competitors include Lucid Diagnostics, PAVmed and Previse.
Castle Biosciences offers TissueCypher, DecisionDx-Melanoma, DecisionDx-SCC, DecisionDx-UM, and MyPath Melanoma.
Castle Biosciences has 8 investors. Key investors include UPMC, Castle Biosciences, NIH, Geisinger, and Ben Franklin Technology Partners.